Myelofibrosis Clinical Trials
Here are the 6 most popular medical studies for myelofibrosis
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Azacytidine for Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm
This trial is testing a combination of two drugs to treat patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm.
Anti-metabolites
Decitabine for Myelofibrosis
This trial looks at the side effects and effectiveness of decitabine in treating patients with myelofibrosis, a cancer of the blood system. Decitabine may block proteins that turn certain genes off in various cancers including myelofibrosis.
Popular filter options for myelofibrosis trials
Primary Myelofibrosis Clinical Trials
View 32 Primary Myelofibrosis medical studies.
JAK Inhibitor
Peritransplant Ruxolitinib for Myelofibrosis
This trial is testing whether a drug can help prevent a condition where the transplanted cells from a donor can attack the body's normal cells and improve transplant outcomes in patients with primary and secondary myelofibrosis.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
PMF Clinical Trials
View 32 PMF medical studies.
JAK Inhibitor
Peritransplant Ruxolitinib for Myelofibrosis
This trial is testing whether a drug can help prevent a condition where the transplanted cells from a donor can attack the body's normal cells and improve transplant outcomes in patients with primary and secondary myelofibrosis.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Phase 3 Myelofibrosis Clinical Trials
View 89 phase 3 myelofibrosis medical studies.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
Protein Therapeutics
Luspatercept for Myelofibrosis
This trial is studying how well luspatercept works in treating patients with myeloproliferative neoplasm-associated myelofibrosis and anemia who are on concomitant Janus kinase 2 inhibitor therapy and who require red blood cell count transfusions.
Bromodomain and Extra-Terminal Protein Inhibitor
Pelabresib for Myelofibrosis
This trial is testing a new drug, pelabresib, to see if it is better than the current best drug, ruxolitinib, for myelofibrosis patients who have not yet been treated with Janus kinase inhibitors.
Bcl-2 Inhibitor
Navitoclax + Ruxolitinib for Myelofibrosis
This trial is investigating whether the combination of navitoclax and ruxolitinib is safe and effective in participants with myelofibrosis. Participants will be assigned to either Arm A or Arm B. Arm A will receive navitoclax and ruxolitinib, while Arm B will receive the best available therapy.
Small Molecule Inhibitor
KRT-232 for Myelofibrosis
This trial will study KRT-232, a new drug that inhibits MDM2, for the treatment of patients with myelofibrosis who are no longer benefiting from treatment with a JAK inhibitor. The trial will be conducted in 2 phases.
Myelofibrosis Clinical Trials With No Placebo
View 89 myelofibrosis medical studies that do not have a placebo group.
JAK Inhibitor
Peritransplant Ruxolitinib for Myelofibrosis
This trial is testing whether a drug can help prevent a condition where the transplanted cells from a donor can attack the body's normal cells and improve transplant outcomes in patients with primary and secondary myelofibrosis.
Anti-metabolites
Decitabine + JAK Inhibitors for Advanced Myeloproliferative Disorders
This trial looks at whether a combination of decitabine, ruxolitinib, and fedratinib may be more effective than chemotherapy or no treatment in patients with myeloproliferative neoplasms.
JAK2 Inhibitor
Pacritinib for Myelofibrosis
This trial is testing a new drug, pacritinib, to see if it is better than the current standard of care for treating patients with primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis who have severe thrombocytopenia (low platelet count). 399 patients will be enrolled and randomly assigned to either pacritinib or the current standard of care. The primary outcome measure is spleen response rate.
View More Myelofibrosis Trials
See another 68 medical studies focused on myelofibrosis.
Frequently Asked Questions
Introduction to myelofibrosis
What are the top hospitals conducting myelofibrosis research?
The quest for effective treatments in the battle against myelofibrosis has brought together top hospitals that specialize in clinical trials. Located in New york, the Icahn School of Medicine at Mount Sinai takes the lead with ten ongoing myelofibrosis trials and a total of 20 completed studies since their first recorded trial back in 2007. Meanwhile, The University of Texas MD Anderson Cancer Center in Houston stands out with seven active myelofibrosis trials and a history of eleven previous investigations dating from their inaugural trial in 2011.
Not to be overlooked is the Gabrail Cancer Center, situated in Canton, which currently runs six active myelofibrosis trials while contributing eight all-time studies since its initial experiment conducted back in 2004. Another reputable institution making strides is MD Anderson Cancer Center, also located in Houston, where researchers are conducting six ongoing clinical trials for myelofibrosis while boasting an impressive track record of nineteen previously conducted studies since embarking on this challenging research path. Lastly yet notably significant is Memorial Sloan Kettering Cancer Center based out of New York City; here five vital current explorations coexist alongside twelve past endeavors stretching as far back as 2009 when they recorded their first ever investigation into tackling Myelofibrosis.
Myelofibrosis - a rare bone marrow disorder characterized by abnormal blood cell production leading to scarring within the bone marrow - affects individuals around the globe and demands relentless efforts from medical professionals to improve patient outcomes and quality of life. These top hospitals dedicated to advancing knowledge through clinical research bring renewed hope not only to those directly affected but also shed light on potential breakthroughs that could impact future treatment options globally.
Which are the best cities for myelofibrosis clinical trials?
When it comes to myelofibrosis clinical trials, several cities have emerged as leading destinations for research and advancements in treatment. New york City takes the lead with 43 active trials focused on innovative approaches such as Arm 3: JAKi Naïve Combination Arm, Navitoclax, FEDRATINIB, among others. Houston, Texas follows closely behind with 34 ongoing studies investigating parsaclisib, KRT-232, Navitoclax, and more. Seattle in Washington state has become another prominent hub with 15 active trials exploring Allogeneic Hematopoietic Stem Cell Transplantation, FEDRATINIB, Bomedemstat, and other potential breakthroughs. These cities along with Ann Arbor (Michigan) and Los Angeles (California) offer individuals battling myelofibrosis access to cutting-edge clinical trials that hold promise for improved outcomes and quality of life.
Which are the top treatments for myelofibrosis being explored in clinical trials?
Myelofibrosis, a complex and challenging condition, is currently the focus of several promising treatments in clinical trials. Among the top contenders are:
- Allogeneic Hematopoietic Stem Cell Transplantation with 4 active trials since 2014.
- TL-895 showing potential in 3 ongoing trials following its introduction in 2020.
- Selinexor making headway with 3 active trials since its listing in 2019.
- KRT-232 also gaining attention through its involvement in 3 ongoing studies starting from 2019.
- Navitoclax, entering the scene in 2017, participating in three current myelofibrosis trials. These innovative therapies offer hope for improved outcomes and quality of life for individuals battling this debilitating disease.
What are the most recent clinical trials for myelofibrosis?
Exciting developments are underway in the field of myelofibrosis research, with recent clinical trials exploring potentially groundbreaking treatments. Among these trials is an investigation into reparixin as a potential therapy for myelofibrosis patients. Another trial focuses on the use of pegylated interferon alpha2a to evaluate its efficacy and safety in treating this condition. Additionally, NS-018 is being studied in phase 2 trials to assess its effectiveness against myelofibrosis. The combination of ruxolitinib and abemaciclib is also under examination, aiming to determine if it can provide improved outcomes for individuals with myelofibrosis. Finally, CK0804 has entered phase 1 trials to explore its potential benefits for those affected by this condition. These exciting endeavors hold promise for advancing treatment options and improving the lives of people living with myelofibrosis.
What myelofibrosis clinical trials were recently completed?
Several noteworthy clinical trials for myelofibrosis have recently concluded, representing significant progress in the search for effective treatments. In July 2021, Incyte Corporation successfully completed a trial investigating itacitinib's potential in combating this challenging condition. Additionally, John Mascarenhas wrapped up a trial involving AVID200 in February 2019. Further groundbreaking research includes Celgene's Luspatercept trial completion in November 2017 and Imago BioSciences' IMG-7289 study conclusion in July 2017. These remarkable advancements highlight the unwavering commitment of researchers towards advancing our understanding and management of myelofibrosis.